12:00 AM
 | 
Aug 17, 2015
 |  BC Week In Review  |  Company News  |  Deals

Biomics Biotechnologies, Benitec deal

Benitec purchased Biomics’ share in DNA-directed RNAi (ddRNAi)-based HBV drug candidate Hepbarna, which the companies had been developing under a...

Read the full 88 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >